Bony

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bony

Quick Facts

Property Description
Active Ingredient Methylprednisolone
Pharmacological Class Glucocorticoid (Corticosteroid)
Common Use Managing severe inflammation and immune response
Origin Synthetic
Forms Tablet, Injection (Solution/Suspension)

What Type of Medicine is Bony?

Bony is a pharmaceutical product containing the powerful synthetic compound methylprednisolone, classifying it as a hormonal medicine. It belongs to the glucocorticoid pharmacological class, a type of corticosteroid intended for systemic use throughout the body. The fundamental identity of Bony is rooted in its active substance, which is a potent derivative designed to mimic the action of natural steroid hormones produced by the adrenal glands.

As a glucocorticoid, Bony is a critical prescription-only (Rx) agent for managing conditions driven by overactive inflammatory or immune responses. Its function is to rapidly modulate immune functions. The synthetic origin of methylprednisolone allows for a focused and potent effect profile compared to less modified natural analogues.


Composition and General Purpose

Bony is formulated as a single-ingredient medicine, with its effect attributed entirely to the active ingredient methylprednisolone. It is available in various dosage forms, including the tablet for oral intake, as well as a solution for injection or suspension for injection for parenteral delivery. This variety of forms ensures suitability for different patient groups and administration settings.

The general purpose of using Bony is to provide relief from severe symptoms associated with widespread inflammation and immune system dysregulation. This is achieved through its two primary actions: profound anti-inflammatory action and significant immunosuppression. The core function is to rapidly turn down the body's overactive inflammatory signals, helping to manage scenarios such as severe allergic reactions or acute autoimmune disorder exacerbations. Methylprednisolone is an essential tool in clinical practice due to its capacity for swift, decisive physiological intervention.

Regulatory References

  1. Methylprednisolone: MedlinePlus Drug Information
  2. Methylprednisolone EMA Referral

What side effects are possible with Bony?

Possible Side Effects and Safety Information

Bony (Alendronate/Bisphosphonate Class) is associated with officially documented adverse reactions primarily affecting the gastrointestinal and musculoskeletal systems, as categorized by major regulatory bodies (e.g., FDA, EMA).


Adverse Reaction Scope

Common adverse reactions (seen in 1 to 10 in 100 patients) often involve the Gastrointestinal Tract, including nausea, abdominal pain, constipation, diarrhea, and gas. Musculoskeletal effects such as headache, dizziness, joint swelling, and muscle cramps are also documented.

Serious and Clinically Significant Risks

Official regulatory sources highlight the risk of several serious adverse reactions:

  • Gastrointestinal Injury: Serious upper GI adverse reactions include esophageal ulceration, erosion, perforation, and hemorrhage, which can occur if the medication is not taken according to specific instructions.
  • Bone Necrosis: A rare but serious condition known as Osteonecrosis of the Jaw (ONJ), particularly following dental procedures, has been reported.
  • Atypical Fractures: Atypical subtrochanteric and diaphyseal femoral fractures (thigh bone) have been reported, often associated with long-term use (typically over five years).
  • Severe Musculoskeletal Pain: Severe bone, joint, or muscle pain has been reported, sometimes beginning days, months, or years after starting the treatment.

Population-Specific Safety Considerations

  • Renal Impairment: The drug is generally contraindicated or requires caution in patients with severe kidney problems due to accumulation risk.
  • Pre-existing Conditions: Caution is advised for patients with pre-existing conditions like hypocalcemia (low blood calcium levels) or severe difficulties with swallowing or the esophagus.

Safety Restrictions and Monitoring

  • Administration Restriction: To mitigate the risk of esophageal damage, the drug is contraindicated if the patient is unable to remain upright (sitting or standing) for at least 30 minutes after taking it. Administration requires remaining upright and using a full glass of plain water.
  • Monitoring: The need for continued therapy, particularly in patients treated for more than five years, should be periodically reevaluated. Patients presenting with new pain in the hip, groin, or thigh require evaluation to rule out a femoral fracture.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose involving Bony (methylprednisolone) is documented as a serious event that requires immediate medical attention. The official regulatory profile characterizes overdose as an exacerbation of known systemic glucocorticoid effects on the body.


Documented Manifestations and Severe Outcomes

Clinical signs of overdose may include disturbances in fluid and electrolyte balance, leading to high blood pressure (hypertension) and swelling (peripheral edema). Neurological manifestations such as altered mental status or convulsions (seizures) are also documented. Of particular concern are the severe outcomes, including the potential development of significant heart rhythm disturbances (cardiac dysrhythmias).


Mandated Emergency Action and Management

In the event of any suspected overdose, government guidance mandates that users call the local emergency number and contact a poison control center immediately. Management is entirely supportive, as no specific antidote is known for methylprednisolone.

Treatment procedures involve symptomatic and supportive care, often requiring hospital monitoring. This includes close observation of vital signs, along with specialized testing such as an ECG (heart tracing) and laboratory assessment of fluid and electrolyte levels.


Population Considerations

A specific regulatory caution notes that infants born to mothers who received substantial doses must be observed for signs of hypoadrenalism.

Therapeutic Uses of Bony

What Bony Treats: Main Uses and Benefits

Bony (methylprednisolone) is a medication used to help manage symptoms related to inflammation and immune response. It is commonly used across multiple medical domains to provide supportive symptomatic relief during episodes where symptoms are driven by heightened physiological activity. Its indications are recognized for easing the symptom burden across various conditions.


Managing Systemic Autoimmunity and Rheumatic Disease Flare-ups

This medication is relevant in conditions characterized by periods of heightened symptoms, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis. It is applied when symptom clusters involving profound swelling, joint pain, and stiffness become more disruptive during flare-ups. This use provides support that helps ease the overall symptom burden during periods of heightened symptoms, and may assist with maintaining functional stability.

Quick Fact: Relief for Severe Inflammation — Bony is often used in settings marked by temporary physiological imbalance, specifically to address the redness, heat, and swelling of joints and tissues.

Controlling Allergic and High-Intensity Inflammatory Needs

Bony is commonly used when short-term symptomatic assistance is needed for conditions involving severe allergic states, asthma, and dermatologic diseases, which create noticeable physiological strain. It is applied in addressing symptom clusters that may become intense or disruptive, such as widespread rash, intense itching, or respiratory distress. The medicine also plays a role in managing exacerbations of multiple sclerosis (MS) and is used in adrenocortical insufficiency to support symptoms linked to organ-specific functional stress.

“The medication assists with maintaining a sense of stability when symptoms are more noticeable, providing symptomatic relief that helps patients cope more steadily.”

This application contributes to improved comfort during periods of heightened symptoms across various conditions involving inflammatory or irritative processes.

Eligibility and Restrictions for Use

Official Eligibility Rules for Bony

Eligibility for Bony (methylprednisolone) is strictly defined by regulatory labeling, outlining populations for whom use is prohibited and those who require conditional use.

Absolute Contraindications

Use is contraindicated in patients with active systemic fungal infections or a known hypersensitivity to the drug or its components. Specific administration routes, including intrathecal and epidural injections, are prohibited. Furthermore, formulations containing benzyl alcohol are contraindicated for use in premature infants.

Restricted and Conditional Use

Use requires caution and close monitoring for patients with conditions that carry an increased risk of complications. This includes patients with renal insufficiency, hypertension, or congestive heart failure due to potential fluid retention. Caution is also advised for those with gastrointestinal issues, such as peptic ulcers or diverticulitis, or infections like latent tuberculosis or ocular herpes simplex.

Age and Reproductive Status

Pediatric patients require monitoring for potential growth and development suppression during prolonged courses of treatment. For pregnancy and lactation, use is conditional: it requires a regulatory assessment that weighs the benefits against the documented hazards to the fetus or infant.

What should I know about interactions with other medicines?

Bony (methylprednisolone) is subject to officially documented interaction patterns primarily centered on its hepatic clearance and combined physiological effects. Co-administration with Mifepristone is a formal contraindication noted in regulatory documents. Additionally, the use of Live or Live, Attenuated Vaccines is prohibited during treatment with immunosuppressive doses of Bony. Use is also restricted in patients with systemic fungal infections.

The medicine's clearance relies heavily on the CYP3A4 enzyme system. Inhibitors of this enzyme, such as ketoconazole, itraconazole, and certain macrolide antibiotics, are documented to reduce Bony's clearance, which officially increases its plasma concentration and the risk of systemic effects. Conversely, CYP3A4 inducers like rifampin or phenytoin are documented to increase Bony's clearance, potentially reducing its overall effectiveness.

Pharmacodynamic interactions are documented with several medicinal products. Combining Bony with NSAIDs is officially noted to increase the risk of gastrointestinal bleeding. Concurrent use with potassium-depleting diuretics enhances the documented risk of hypokalemia. Bony may also counteract the effects of antidiabetic agents (e.g., insulin, metformin), reducing their efficacy. Furthermore, grapefruit juice is documented to increase Bony exposure, while the herbal product Echinacea may decrease its effectiveness. Patients with cirrhosis may also experience enhanced systemic effects of Bony, altering the interaction profile.

Mechanism of Action

How Bony Works


Molecular Control of Gene Expression and Signaling

Methylprednisolone acts as an agonist of the Intracellular Glucocorticoid Receptor ( GR), a protein found inside cells. The activated drug-receptor complex enters the nucleus and regulates gene expression, effectively functioning as a genetic switch. This action involves transactivation (upregulating anti-inflammatory proteins) and transrepression (directly suppressing the genetic signals for pro-inflammatory substances like cytokines and transcription factors such as NF-kappa B). This core mechanism establishes a sustained shift in the cellular output toward an anti-inflammatory and immunosuppressive profile.


Central Suppression of the Inflammatory Cascade

A direct consequence of genetic regulation is the increased production of Lipocortin-1 ( Annexin A1), which acts as an indirect inhibitor of the enzyme Phospholipase A2 ( PLA2). By blocking PLA2, the drug prevents the release of Arachidonic Acid, the precursor required for the body to synthesize all major inflammatory mediators, including prostaglandins and leukotrienes. This central inhibition simultaneously modulates multiple inflammatory pathways and contributes to the resulting physiological state.


Modulation of Immune Cell Function and Kinetics

The drug's mechanism extends beyond biochemical suppression by modulating the function of immune cells. It significantly suppresses the proliferation of T and B lymphocytes and interferes with the adhesion and migration of immune cells (like monocytes and eosinophils) into affected tissues. This systemic modulation of immune cell kinetics and function leads to an overall immunosuppressive state.

Dosage and Administration Information

How Bony is Used: Administration Guidelines

Bony (methylprednisolone) is a medicine whose administration is defined by a multi-route protocol and specific dosage schedules outlined in prescribing information. The drug may be delivered orally as a tablet, or parenterally via intravenous (IV), intramuscular (IM), intra-articular, and intralesional injection using different salt forms.


Dosing and Frequency

For systemic oral use, initial daily dosages generally range from 4 mg to 48 mg, which may be taken once daily or in divided doses. The regimen may shift to Alternate Day Therapy (ADT) for long-term management, administering twice the daily dose every other morning to influence physiological rhythm. For severe, acute episodes, high-dose IV pulse therapy can involve up to 30 mg/kg, administered every 4–6 hours, with the infusion requiring a minimum of 30 minutes for larger doses.


Administration Constraints

Oral tablets may be taken with food or milk to aid gastrointestinal tolerability. The injectable sodium succinate form must not be mixed or diluted with other solutions apart from the designated diluent. Furthermore, for pediatric patients, the lowest possible dose necessary to control the condition is the governing principle. Following prolonged therapy, the medicine must be withdrawn gradually (tapering) rather than abruptly, and dosage may need temporary increases during periods of unusual physiological stress.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bony (Methylprednisolone)

Bony, which contains the active ingredient methylprednisolone, is a type of medicine whose clinical evaluation relies on research described in authoritative sources, including Randomized Controlled Trials (RCTs) and systematic reviews. The research landscape outlines what kinds of evidence exist, what outcomes studies monitored, and the areas where data remain limited or inconsistent.

Evidence for Managing Systemic Autoimmune and Rheumatic Disease Flares

This section will summarize the structure of research, including Randomized Controlled Trials (RCTs) and systematic reviews, examining Bony's role in the acute management of conditions such as Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA). The focus will be on the types of outcomes measured, such as disease activity scores and inflammatory markers.

Research on Acute Symptoms in Rheumatoid Arthritis

Research has actively studied Bony for use in conditions characterized by fluctuating or episodic manifestations, particularly periods of heightened symptoms in Rheumatoid Arthritis (RA). Studies explored short-term symptom changes, often looking at Bony in combination with other disease-modifying anti-rheumatic drugs (DMARDs).

Research describes patterns of changes in outcomes linked to inflammatory or irritative states that were observed during the study periods. What remains uncertain is the full picture of the treatment when used alone, as most evidence involves patients already taking other RA medications. Additionally, follow-up durations were limited in some studies, meaning there is limited information for long-term outcomes regarding the patterns of change after the initial study phase concludes.

Evidence for Controlling Severe Acute Inflammatory States

This section will provide an overview of the evidence structure, including clinical consensus and systematic reviews of the glucocorticoid class, supporting Bony's application in various high-intensity conditions. It will focus on how studies addressed acute scenarios such as severe asthma exacerbations and other acute allergic or dermatologic states, as well as its established role in adrenocortical insufficiency.

Studies on Acute Multiple Sclerosis Relapses

Bony was studied for conditions associated with acute or disruptive episodes, specifically Multiple Sclerosis (MS) relapses. Studies explored short-term symptom changes using neurological scales and tracked inflammation via MRI scans. Findings describe patterns observed in the studies that focus on the timing of initial change following the acute episode.

A key limitation is that these studies are designed to look at acute change, not disease progression. The research provides context but not individual predictions about the long-term course of MS. Limited information for long-term outcomes is available regarding whether Bony impacts the frequency of future relapses or overall accumulation of disability.

What is Still Uncertain About Bony Research

Evidence highlights what is known—and what is still uncertain—about Bony's research profile. The evidence quality varies across studies, particularly for long-established acute uses where such comparative evidence is often limited. Key gaps include limited information for long-term outcomes regarding the prevention of disease damage or the patterns of stability of symptoms after treatment ends, especially when Bony is not used as part of a chronic replacement regimen.

Key Studies & References METHYLPREDNISOLONE tablet (DailyMed - NIH)

Frequently Asked Questions (FAQ)

Common questions about Bony (FAQ)

Q: Is it normal to feel a bit drowsy when first starting Bony?

A: Official documentation for this medicine notes potential central nervous system adverse reactions, such as dizziness and headache. While drowsiness is not consistently listed, official documentation does note related effects like dizziness, which can influence a person's level of alertness. Additionally, feelings of unusual tiredness are listed as a symptom associated with the serious side effect of adrenal insufficiency.

Q: What is the risk of dependence or withdrawal associated with Bony?

A: Prolonged therapy with Bony can lead to a condition called secondary adrenocortical insufficiency. This can result in the body not producing enough natural steroids, an effect that may continue for a period after the medicine is discontinued. To prevent this serious condition, official documents caution that the medicine must be withdrawn gradually (tapering) rather than stopped suddenly.

Q: Is Bony considered a new or established treatment option?

A: Bony’s active ingredient, methylprednisolone, is indicated for a broad range of established conditions, including certain rheumatic, allergic, and endocrine disorders. Its use is defined by a broad range of established indications in the official labeling, which supports its long-standing role as a glucocorticoid medicine.

Q: Do older adults (seniors) need to take Bony differently?

A: Official labeling advises that dose selection for older patients should generally be approached with caution. This is primarily because older individuals may have a greater frequency of decreased liver or kidney function, which affects how the medicine is cleared from the body. Regulatory documents state that when selecting a dose, it is generally prudent to consider starting at the low end of the dosing range.

Q: Is it okay to take common pain relievers, like ibuprofen, while on Bony?

A: The official interaction profile documents that taking Bony alongside Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, is associated with a documented increased risk of gastrointestinal bleeding. This is an officially noted risk in the product labeling.

Q: Does Bony affect the results of routine lab tests?

A: The medicine can influence test results. Bony may suppress reactions to skin tests, such as those used for tuberculosis screening. Due to its systemic action on the immune system, it may also affect the results of certain antibody-based blood tests.

Q: Is Bony known to cause weight gain or loss in clinical studies?

A: Official product information lists weight gain as a common adverse reaction associated with this medication. This is often noted in association with the drug's effects on fluid balance and appetite.

Q: Are there any known interactions between Bony and common herbal teas or supplements?

A: Regulatory documents describe interactions with certain botanical and food products. The interaction profile notes that Grapefruit juice can increase the amount of the drug in the body. Conversely, the herbal supplement Echinacea is documented to potentially decrease Bony's effectiveness.

Q: Can Bony be taken by people with a history of heart rhythm problems?

A: The official warnings state that caution is advised for use in patients with a history of congestive heart failure and high blood pressure (hypertension). Bony can cause fluid retention and potassium loss, both of which are documented effects that can influence cardiovascular status.

Q: Does the time of day Bony is taken affect its effectiveness or side effects?

A: Official documents outline a dosing strategy called Alternate Day Therapy (ADT) for some long-term uses. This regimen involves taking the dose every other morning; regulatory information indicates this timing is intended to influence the body's natural hormonal rhythm.

Q: What steps are officially recommended if a dose of Bony is missed?

A: According to the patient information leaflet, a missed dose should generally be taken as soon as the patient remembers. However, if it is almost time for the next scheduled dose, the regulatory guidance is to consider skipping the missed dose and waiting for the next one to avoid taking too much medicine in close succession.

Q: How does Bony affect general energy levels, according to patient reports?

A: Official labeling lists psychiatric side effects such as insomnia (trouble sleeping) and euphoria or mood swings, which can naturally influence perceived energy levels. Furthermore, unusual tiredness is listed as a symptom associated with the serious effect of secondary adrenocortical insufficiency. These are part of the reported adverse reactions associated with the medicine's systemic action.

Q: Are there any warnings regarding driving or operating heavy machinery while using Bony?

A: The medicine is associated with neurological adverse reactions, including dizziness, vertigo, and headache. Official guidance usually recommends caution for patients experiencing these effects when performing skilled tasks like driving or operating machinery.

Q: Can Bony be used in teenagers or children under certain conditions?

A: Bony is indicated for a number of conditions that affect pediatric patients, such as acute leukemia of childhood and juvenile rheumatoid arthritis. However, official warnings caution that children on prolonged therapy must be monitored for potential growth and development suppression.

Q: Does Bony carry any specific warnings for people with diabetes?

A: Official documentation notes that Bony may cause decreased carbohydrate tolerance and is noted to potentially bring about latent diabetes. Patients who already have diabetes may require an increased amount of insulin or oral antidiabetic agents while on this medicine.

Q: Why might a doctor adjust the amount of Bony a person is taking?

A: Dosing is often adjusted to achieve the lowest possible amount that still produces an adequate clinical response. Official guidelines also note that the dosage may need to be temporarily increased during periods of unusual physiological stress, such as surgery or illness.

Q: What kind of monitoring is typically done by doctors when a patient is on Bony?

A: Monitoring instructions are in place to address specific risks. This includes the need to evaluate patients for potential femoral fractures if they present with new pain in the hip or thigh. Doctors are also noted to monitor for signs of fluid retention and high blood pressure.

Q: Why do some people refer to Bony as a 'maintenance' medication?

A: The medicine is officially indicated for use as maintenance therapy in selected cases of chronic conditions, such as certain autoimmune disorders. This terminology is used in official documentation when referring to the use of a low-dose maintenance regimen for managing symptoms over a long period.

Q: Why do official documents caution against suddenly stopping Bony?

A: Official documents caution against abrupt cessation to prevent a serious complication called adrenocortical insufficiency. This happens because the body, having relied on the medicine, is unable to produce the necessary amount of its own natural steroid hormones when the drug is suddenly removed.

Q: Does Bony interact with common birth control pills?

A: The drug's breakdown in the body involves the CYP3A4 enzyme system. Since some hormonal contraceptives are also processed by this system, official sources indicate that an interaction is possible which may alter the levels of both Bony and the contraceptive in the bloodstream.

Q: What are the less common, but reported, skin side effects of Bony?

A: Reported skin-related adverse reactions in official labeling include impaired wound healing and skin changes like thin fragile skin. Other reported effects are small red spots (petechiae), bruising (ecchymoses), and generalized facial redness (facial erythema).

Q: How long does Bony stay in the body after the last dose?

A: Based on pharmacokinetics, the drug's elimination half-life is documented to be between 2.5 to 3.5 hours. Based on this half-life, the drug is typically estimated to be largely cleared from the system within approximately 14 to 20 hours.

Q: Is Bony known to cause issues with sleep or insomnia?

A: Yes, official documentation lists insomnia (difficulty falling or staying asleep) as a reported psychiatric adverse reaction associated with the use of this medicine. This is listed as a reported adverse reaction associated with the medicine.

How should Bony be stored and disposed of?

How to Store and Dispose of Bony (Methylprednisolone)

Bony (methylprednisolone) must be stored in specific environmental conditions defined by regulatory labeling to maintain its stability.

Storage Requirements

Labeled Condition Instruction
Temperature Store at controlled room temperature (20 C to 25 C). Do not store above 30 C.
Protection Keep the container tightly closed and protect from moisture.
Child Safety Keep this medication out of the sight and reach of children.

Disposal Instructions

Unused or expired Bony should be discarded using an official drug take-back program when available. If a take-back program is not accessible, the medicine must be mixed with an undesirable substance and placed in a sealed bag before disposal in the trash. Do not flush the medication down the toilet or pour it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bony found in:

A-Z Index: